Coadministration of 5% glucose solution relieves vascular pain in the patients administered gemcitabine immediately

Abstract

Get full access to this article

View all access options for this article.

References

Aapro

Martin

Hatty

. Gemcitabine – a safety review. Anticancer Drugs 1998; 9(3): 191–201.

Nagai

Yasuda

Kanai

. A double-blind, randomized, multicenter study regarding the effects of solution for gemcitabine on frequency and degree of vascular pain in patients with cancer. J Clin Oncol 2011; 29(Suppl): abstract e19642–abstract e19642.

Rutherford

Rooke

Joyce

Uncommon arteriopathies. In: Rutherford

(eds). Vascular surgery, 5th edn. Philadelphia, PA: WB Saunders, 2000, pp. 418–419.

Birlik

Akar

Tuzel

. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder. J Cancer Res Clin Oncol 2004; 130(2): 122–125.

Voorburg

van Beek

Slee

. Vasculitis due to gemcitabine. Lung Cancer 2002; 36(2): 203–205.

Vénat-Bouvet

Szelag

. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. Anticancer Drugs 2003; 14(10): 829–832.

Niho

Kubota

Goto

. Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study. Br J Cancer 2002; 87(12): 1360–1364.

Dasanu

. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008; 7(6): 703–716.

Kucukarslan

Guler

Pocan

. An unusual etiology of vascular toxicity and its treatment with cervical sympathetic blockage. Internet J Thorac Cardiovasc Surg (Internet Scientific Publications) 2006; 8(1): Internet Scientific Publications.

10.

Zhang

Trissel

. Physical and chemical stability of gemcitabine hydrochloride solutions. J Am Pharm Assoc (Wash DC) 1999; 39(4): 509–513.

11.

Hockenberry

Wilson

. Wong’s essentials of pediatric nursing, 8th edn. St Louis, MO: Mosby, 2009.

12.

Veltkamp

Beijnen

Schellens

. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008; 13(3): 261–276.

13.

Poplin

Levy

Berlin

. Phase III trial of gemcitabine (30 min infusion) versus gemcitabine (fixed-dose-rate infusion [FDR] versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006; 24(18S): LBA4004–LBA4004.

14.

Hospira Healthcare Corporation. Gemcitabine for injection, USP product monograph. Montreal, Quebec, 3 November 2008.

15.

Holstein

Bätge

Egberts

. Gemcitabine induced digital ischaemia and necrosis. Eur J Cancer Care (Engl) 2010; 19(3): 408–409.

16.

Corella

Dalmau

Roe

. Cutaneous vasculitis associated with gemcitabine therapy. Clin Exp Dermatol 2008; 34(1): 81–105.

17.

Barceló

López-Vivanco

Mañé

. Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases. Ann Oncol 2000; 11(9): 1191–1194.

18.

Içli

Karaoğuz

Dinçol

. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72(2): 587–593.

19.

PMDA. Prescribing information from the PMDA about GEMZAR® (gemcitabine). http://www.info.pmda.go.jp/go/pack/4224403D1030_1_12 (2011, accessed 23 February 2012).

20.

Lilly. Prescribing information from the FDA about GEMZAR® (gemcitabine). http://pi.lilly.com/us/gemzar.pdf (2011, accessed 3 February 2012).